Evidence item

The results passage reports 22 of 40 objective responses and 95.0% disease control. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 14578

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:ff58d14e7ffeadae9ea75b3342f3e655988e20bb2093b11df8e1d3095e8d1d61

The ORR was 55% (22/40; 95% CI 38.5–70.7) ... and the DCR was 95.0% (95% CI 83.5–99.4).